News Category AllAll ReleasesRegulatory Releases Year All2024202320222021202020192018 May 17, 2024 Oculis updates share capital for its existing at-the-market offering program May 8, 2024 Oculis Reports Q1 2024 Financial Results and Provides Company Updates May 8, 2024 Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis May 6, 2024 Oculis to Present at Bank of America Global Healthcare Conference April 22, 2024 Oculis Mourns the Loss of Chief Scientific Officer Professor Ramin Tadayoni April 11, 2024 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market April 10, 2024 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development April 8, 2024 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting April 4, 2024 Oculis to Participate at Upcoming April Investor Conferences March 18, 2024 Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
May 8, 2024 Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
April 11, 2024 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
April 10, 2024 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
April 8, 2024 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting